US 12,403,133 B2
Rifabutin treatment methods, uses, and compositions
Glenn E. Dale, Basel (CH); Sergio Lociuro, Basel (CH); Marc Gitzinger, Laufenburg (CH); Stefano Biondi, Basel (CH); and Marilyne Bourotte, Perenchies (FR)
Assigned to BIOVERSYS AG, Basel (CH)
Filed by BIOVERSYS AG, Basel (CH)
Filed on Feb. 7, 2024, as Appl. No. 18/435,221.
Application 18/435,221 is a continuation of application No. 17/826,817, filed on May 27, 2022, granted, now 11,903,934.
Application 17/826,817 is a continuation of application No. 16/983,667, filed on Aug. 3, 2020, granted, now 11,344,537, issued on May 31, 2022.
Claims priority of provisional application 62/977,659, filed on Feb. 17, 2020.
Claims priority of provisional application 62/941,160, filed on Nov. 27, 2019.
Claims priority of provisional application 62/902,019, filed on Sep. 18, 2019.
Prior Publication US 2024/0197697 A1, Jun. 20, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/438 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01)
CPC A61K 31/438 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0073 (2013.01); A61K 9/08 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A rifabutin formulation produced from a rifabutin powder in the presence of an acid, water, and a solvent with a rifabutin concentration of greater than or equal to about 250 mg/mL.